Pau Riera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3867683/publications.pdf

Version: 2024-02-01

1163117 1125743 20 183 8 13 citations h-index g-index papers 20 20 20 371 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy, 2022, 44, 725-730.	2.1	6
2	Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1157-1163.	3.3	5
3	Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients Farmacia Hospitalaria, 2021, 45, 5-10.	0.6	O
4	Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition. Nutrition in Clinical Practice, 2020, 35, 967-972.	2.4	5
5	ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in Pharmacology, 2020, 11, 973.	3 . 5	14
6	Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 2245.	3.7	2
7	Targeted Next-Generation Sequencing in a Large Cohort of Genetically Undiagnosed Patients with Neuromuscular Disorders in Spain. Genes, 2020, 11, 539.	2.4	25
8	Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3044-3057.	7.0	23
9	Physicochemical Compatibility of Amiodarone with Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2019, 43, 298-304.	2.6	9
10	Comments on: $\hat{a} \in \infty$ Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan $\hat{a} \in \mathbb{R}$ Pharmacological Research, 2019, 145, 104287.	7.1	0
11	Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis, 2019, 22, 433-440.	7.2	28
12	Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. British Journal of Cancer, 2019, 120, 190-195.	6.4	31
13	Physicochemical Stability and Sterility of Standard Parenteral Nutrition Solutions and Simulated Yâ€Site Admixtures for Neonates. Nutrition in Clinical Practice, 2018, 33, 694-700.	2.4	8
14	Relevance of <i>CYP3A4*20</i> , <i>UGT1A1*37</i> and <i>UGT1A1*28</i> variants in irinotecanâ€induced severe toxicity. British Journal of Clinical Pharmacology, 2018, 84, 1389-1392.	2.4	19
15	Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. Pharmacogenomics Journal, 2018, 18, 556-564.	2.0	7
16	Relevance of the CYP3A4*20 variant as a predictor of paclitaxel-induced neuropathy in the Spanish population. Medicina ClĀnica (English Edition), 2018, 150, 163-164.	0.2	0
17	Relevancia de la variante CYP3A4*20 como predictor de neuropatÃa inducida por paclitaxel en población española. Medicina ClÃnica, 2018, 150, 163-164.	0.6	1
18	Physicochemical compatibility of dexmedetomidine with total parenteral nutrition. Clinical Nutrition, 2018, 37, S312-S313.	5.0	0

#	Article	IF	CITATIONS
19	Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype. Annals of Oncology, 2017, 28, iii12.	1.2	0
20	Prognostic factors and specific populations in the pharmacogenetic randomized phase II trial of FOLFIRI with high-dose (HD) of irinotecan vs standard doses in metastatic colorectal cancer (mCRC) patients (pts) according to UGT1A1 genotype. Annals of Oncology, 2017, 28, v180.	1.2	0